GlassScriptPhysician profile
David J Krempa
NPI 1780753038
$12,205.29
in general payments reported to CMS, 2019-2025
36 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $2,178 · 2021: $2,183 · 2022: $1,816 · 2023: $1,665 · 2024: $1,729 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,526.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,953.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,529.83 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,527.04 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,364.82 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $990.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $684.09 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $570.22 | 2020-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $566.92 | 2019-2024 | Seglentis, Livalo |
| Amarin Pharma, INC. | $464.33 | 2019-2022 | |
| Grifols USA, LLC | $450.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $294.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $242.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $242.58 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $224.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $154.73 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Krempa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.